Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Nightingale's tests integrated into Siun sote's health checks

HEALTHAnalyst Comment2026-10-06 08:11
Antti SiltanenAnalyst
Discuss

Summary

  • Nightingale Health announced that its disease risk detection will be integrated into health checks for the unemployed in North Karelia, Finland, starting in October 2026, marking a significant entry into public primary healthcare.
  • The integration involves blood tests providing risk estimates for chronic diseases, with high-risk individuals directed into existing care pathways, showcasing a low-threshold solution that fits into current healthcare processes.
  • The pilot's initial volumes are expected to be small, with no immediate financial impact on Nightingale, but it supports expectations for gradual technology integration into broader healthcare systems.
  • Successful results from the pilot are crucial for Nightingale's growth, as larger contracts in the public sector require evidence of impact and cost-efficiency, with the Siun sote model potentially serving as a reference for other regions.

This content is generated by AI. You can give feedback on it in the Inderes forum.

Translation: Original published in Finnish on 10/06/2026 at 07:35 am EEST

Nightingale Health announced on Monday that the Wellbeing Services County of North Karelia (Siun sote) will integrate the company's disease risk detection into health checks for the unemployed in a pilot starting in October 2026. We view the news as a positive step, as public primary healthcare is a significant potential market for the company, and breaking into it is traditionally slow and difficult. While this is a significant breakthrough in statutory health checks in the public sector, we estimate that the pilot's early-stage volumes, and thus its immediate financial significance, will remain small on the company’s scale. Thus, the news does not cause immediate changes to our estimates, but it partly supports our expectations regarding the gradual integration of the company's technology into broader healthcare processes.

Opening up statutory services in the public sector

With the agreement, Nightingale's blood test will be integrated into Siun sote's health checks for the unemployed, which are a statutory service provided by the Wellbeing Services Counties for individuals outside of occupational healthcare. Customers will have blood tests before the appointment, and Nightingale will provide risk estimates for five common chronic diseases (including type 2 diabetes and heart attack). High-risk customers are directed into existing care pathways, and the development of risks is subsequently monitored with follow-up samples. North Karelia is the first Wellbeing Services County to take the test as a routine part of statutory health checks. We have previously emphasized that the value of Nightingale's solution is measured by how well it can be integrated into existing care chains without heavy new infrastructure. We believe that the Siun sote model, where the test is performed as part of routine sampling, and the results are linked directly to existing digital care pathways, appears to be precisely this kind of low-threshold solution.

Volume growth requires successful results from the pilot phase

We believe Nightingale’s value creation relies on strong growth in test volumes. The company already has an ongoing Hyvinvointilahja project in the public sector with the Wellbeing Services County of South Savo (Eloisa). We have estimated that acquiring public sector customers is slow and that larger contracts necessitate indisputable evidence of the impact and cost-efficiency of the pilots. We believe that the data on morbidity and the impact of interventions collected in the Siun sote pilot is critical for the company's future sales. As an individual pilot, we estimate that the volume brought by Siun sote will not yet resolve the company's growth challenges for the coming years or the risks related to cash burn. However, if successful, the model can serve as an important reference for other Wellbeing Services Counties. Regarding the investment story, our main focus remains on how the volumes of the largest international partnerships scale.

 

Nightingale Health operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio is broad and includes platforms and services within blood analysis that are used for disease prevention purposes. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in Europe.

Read more on company page

Key Estimate Figures16/09

202627e28e
Revenue5.510.211.0
growth-%17.2 %84.5 %8.4 %
EBIT (adj.)-18.8-15.0-14.1
EBIT-% (adj.)-341.8 %-147.8 %-127.9 %
EPS (adj.)-0.30-0.25-0.23
Dividend0.000.000.00
Dividend %
P/E (adj.)neg.neg.neg.
EV/EBITDAneg.neg.neg.

Forum discussions

More information about the Alamar NULISA panel used by Nightingale can be found in the link below. research.nightingalehealth.com Nightingale...
10 hours ago
by Pertti
2
Tässä on Siltasen kommentit vielä tuohon, kun Pohjois-Karjalan hyvinvointialue ottaa sairastumisriskien tunnistuksen osaksi työttömien terveystarkastu...
18 hours ago
by Sijoittaja-alokas
8
Out of interest, I looked closer into Alamar and its business model. Quite an interesting clip on YouTube. Investor-oriented speculation… Only...
yesterday
by Cle
17
Inderes Nightingale Healthin sairastumisriskien tunnistus osaksi työttömien... Nightingale Health Oyj | Lehdistötiedote | 05.10.2026 klo 10:...
yesterday
by Pertti
16
Nightingale Health Shares Surge 32 Percent – New Order Exceeds Entire Previous Year’s Revenue A EUR 5.8 million protein analysis order from ...
10/2/2026, 12:10 PM
by TO
11
The AGM is also only coming up due to that non-calendar financial year: Kutsu Nightingale Health Oyj:n varsinaiseen yhtiökokoukseen - Inderes...
10/1/2026, 3:34 PM
by NukkeNukuttaja
4
The margin side is interesting—if they’re paid $108/test, you’d think there would be more left over than the €20-30 from a basic sample Almar...
10/1/2026, 2:25 PM
by Ossi
0